Team Grant: ME/CFS Collaborative Project (Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Collaborative Project)
Well-being, Health and Biomedical Discovery
Deadlines
Academic Unit: Inquire with Unit
Memorial Deadline: Friday 1st, June 2018
External Deadline: Wednesday 6th, June 2018
Description
This funding opportunity will support one team to participate in the ME/CFS Initiative’s collaborative projects that are relevant to one or more of the following areas:
- Studies determining the etiology and pathogenesis of ME/CFS;
- Studies that help to identify subtypes of ME/CFS based on biological markers and/or symptom classifications;
- Longitudinal studies to understand the course of disease to better characterize the manifestations of ME/CFS, and to develop and validate outcome measures for future intervention trials; and
- Studies that identify of potential treatment targets for ME/CFS.
A supplementary amount is also available to this team for research that addresses vascular instability and/or sleep disturbances experienced by people with ME/CFS.
Funds Available
CIHR and partner(s) financial contributions for this initiative are subject to availability of funds. Should CIHR or partner(s) funding levels not be available or are decreased due to unforeseen circumstances, CIHR and partner(s) reserve the right to reduce, defer or suspend financial contributions to the grant received as a result of this funding opportunity.
- The total amount available from CIHR for this funding opportunity is $1,775,000, enough to fund one (1) team. This amount may increase if additional funding partners participate.
- The maximum amount for the grant is $280,000 per year for up to five (5) years, for a total of up to $1.4 million, for the participation of one team in the ME/CFS Initiative Collaborative Project.
- A supplementary amount of $75,000 per year for up to five (5) years, for a total of $375,000, is available to the above team for a project that also addresses vascular instability and/or sleep disturbances experienced by people with ME/CFS.